Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Shusuke, Yoshikawa"'
Autor:
Kenjiro Namikawa, Takamichi Ito, Shusuke Yoshikawa, Koji Yoshino, Yukiko Kiniwa, Shuichi Ohe, Taiki Isei, Tatsuya Takenouchi, Hiroshi Kato, Satoru Mizuhashi, Satoshi Fukushima, Yosuke Yamamoto, Takashi Inozume, Yasuhiro Fujisawa, Osamu Yamasaki, Yasuhiro Nakamura, Jun Asai, Takeo Maekawa, Takeru Funakoshi, Shigeto Matsushita, Eiji Nakano, Kohei Oashi, Junji Kato, Hisashi Uhara, Takuya Miyagawa, Hiroshi Uchi, Naohito Hatta, Keita Tsutsui, Taku Maeda, Taisuke Matsuya, Hiroto Yanagisawa, Ikko Muto, Mao Okumura, Dai Ogata, Naoya Yamazaki
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17967-17980 (2023)
Abstract Background Anti‐PD‐1‐based immunotherapy is considered a preferred first‐line treatment for advanced BRAF V600‐mutant melanoma. However, a recent international multi‐center study suggested that the efficacy of immunotherapy is po
Externí odkaz:
https://doaj.org/article/7bd38e76e920444a8356acd6025d9a4c
Autor:
Tatsuhiko Mori, Kenjiro Namikawa, Naoya Yamazaki, Yukiko Kiniwa, Osamu Yamasaki, Shusuke Yoshikawa, Takashi Inozume, Hiroshi Kato, Yasuo Nakai, Satoshi Fukushima, Tatsuya Takenouchi, Takeo Maekawa, Shigeto Matsushita, Atsushi Otsuka, Motoo Nomura, Natsuki Baba, Taiki Isei, Shintaro Saito, Noriki Fujimoto, Ryo Tanaka, Takahide Kaneko, Yutaka Kuwatsuka, Taisuke Matsuya, Kotaro Nagase, Masazumi Onishi, Takehiro Onuma, Yasuhiro Nakamura
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundAnti-programmed cell death protein 1 (PD-1) monotherapy is one of the standard systemic therapies for advanced melanoma; however, the efficacy of salvage systemic therapies after PD-1 monotherapy failure (PD-1 MF), particularly in acral mel
Externí odkaz:
https://doaj.org/article/d92b81c82c6941559fafef15d965897b
Autor:
Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa, Tatsuya Takenouchi, Kenji Yokota, Hiroshi Uchi, Naoki Noma, Yasuhiro Nakamura, Jun Asai, Junji Kato, Susumu Fujiwara, Satoshi Fukushima, Jiro Uehara, Toshihiko Hoashi, Tatsuya Kaji, Taku Fujimura, Kenjiro Namikawa, Manabu Yoshioka, Naoki Murao, Dai Ogata, Kanako Matsuyama, Naohito Hatta, Yoshitsugu Shibayama, Toshiharu Fujiyama, Masashi Ishikawa, Daisuke Yamada, Akiko Kishi, Yoshiyuki Nakamura, Takatoshi Shimiauchi, Kazuyasu Fujii, Manabu Fujimoto, Hironobu Ihn, Norito Katoh
Publikováno v:
Cancer Medicine, Vol 8, Iss 5, Pp 2146-2156 (2019)
Abstract Background The incidence of melanoma among those of an Asian ethnicity is lower than in Caucasians; few large‐scale Asian studies that include follow‐up data have been reported. Objectives To investigate the clinical characteristics of J
Externí odkaz:
https://doaj.org/article/802d78882fa24ba7ba61619140790c43
Autor:
Takashi Inozume, Kenjiro Namikawa, Hiroshi Kato, Shusuke Yoshikawa, Yukiko Kiniwa, Koji Yoshino, Satoru Mizuhashi, Takamichi Ito, Tatsuya Takenouchi, Shigeto Matsushita, Yasuhiro Fujisawa, Takamitsu Matsuzawa, Satoru Sugihara, Jun Asai, Hiroshi Kitagawa, Takeo Maekawa, Taiki Isei, Masahito Yasuda, Naoya Yamazaki, Hisashi Uhara, Yasuhiro Nakamura
Publikováno v:
Journal of Dermatological Science. 110:19-26
Autor:
Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Yutaka Kuwatsuka, Kotaro Nagase, Takehiro Onuma, Motoo Nomura, Yoshiyasu Umeda, Naoya Yamazaki
Publikováno v:
European Journal of Cancer. 176:78-87
Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefo
Autor:
Keisuke Goto, Shusuke Yoshikawa, Toshihiro Takai, Kota Tachibana, Keiichiro Honma, Taiki Isei, Yoji Kukita, Takuma Oishi
Publikováno v:
Journal of Cutaneous Pathology.
Autor:
Yoshimi Kiyozumi, Keisuke Goto, Shusuke Yoshikawa, Yoshio Kiyohara, Takahiro Tsushima, Nobuhiro Kado, Seiichiro Nishimura, Satomi Higashigawa, Rina Harada, Kana Kunitomo, Naomi Fukuzaki, Hiroyuki Matsubayashi
Publikováno v:
Journal of Human Genetics. 68:359-361
Autor:
Shota, Bun, Keisuke, Goto, Takuma, Oishi, Yoshio, Kiyohara, Arata, Tsutsumida, Shusuke, Yoshikawa
Publikováno v:
The American Journal of Dermatopathology. 44:850-854
Sweat gland carcinoma with neuroendocrine differentiation (SCAND) is a newly proposed tumor entity of primary cutaneous apocrine/eccrine adnexal tumor with neuroendocrine differentiation. The histopathologic variations are not yet well known. In this
Autor:
Keisuke, Goto, Shusuke, Yoshikawa, Yoshio, Kiyohara, Toru, Kurimoto, Kyoko, Nomi, Kohei, Ogawa, Koichiro, Tasaki, Manami, Kajiwara, Toshitaka, Nagao, Kazuhiko, Umazume, Takuma, Oishi
Publikováno v:
The American Journal of Dermatopathology. 44:718-727
This study sought to reveal the clinicopathologic characteristics of large cell neuroendocrine carcinoma (LCNEC) of the skin/conjunctiva. The retrieved patients included 3 men and 3 women with a median age of 85 (63-95) years. All lesions occurred on
Autor:
Yasuhiro Fujisawa, Kenjiro Namikawa, Koji Yoshino, Yukiko Kiniwa, Takamichi Ito, Hiroshi Kato, Shigeto Matsushita, Toshihiko Hoashi, Yasuhiro Nakamura, Shusuke Yoshikawa, Takuya Miyagawa, Jun Asai, Taisuke Matsuya, Satoshi Fukushima, Jyunji Kato, Tatsuya Takenouchi, Hiroshi Uchi, Mamiko Masuzawa, Teruki Yanagi, Takeo Maekawa
Publikováno v:
British Journal of Dermatology.
In Japanese melanoma patients, the response rate of N/I was lower (35.1%) and the rate of adverse events was similar (60.4%) compared to those reported in previous clinical trials. No survival difference was observed with the use of N/I between clini